Goldman Sachs Group Inc. Buys Shares of 20,856 Metsera Inc. $MTSR

Key Points

• Goldman Sachs Group Inc. has acquired a new stake in Metsera Inc. by purchasing 20,856 shares valued at approximately $568,000 during the 1st quarter.
• Other institutional investors have also increased their holdings in Metsera, with significant purchases from entities like Corebridge Financial Inc. and MetLife Investment Management LLC, further demonstrating growing interest in the company.
• Metsera's stock currently holds a consensus rating of "Moderate Buy" with an average target price of $58.50, according to equities research analysts.

Goldman Sachs Group Inc. bought a new stake in Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 20,856 shares of the company's stock, valued at approximately $568,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MTSR. Strs Ohio purchased a new position in shares of Metsera in the 1st quarter worth approximately $76,000. New York State Common Retirement Fund purchased a new position in Metsera in the first quarter worth $131,000. Corebridge Financial Inc. purchased a new position in Metsera during the 1st quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Metsera during the 1st quarter worth $248,000. Finally, MetLife Investment Management LLC purchased a new position in Metsera during the 1st quarter worth $254,000.

Metsera Stock Up 0.0%

MTSR stock opened at $52.51 on Friday. The firm's fifty day simple moving average is $36.25 and its 200-day simple moving average is $29.87. Metsera Inc. has a 12 month low of $12.30 and a 12 month high of $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 price target on the stock. Guggenheim boosted their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Leerink Partners reissued a "market perform" rating and set a $57.00 target price (down previously from $77.00) on shares of Metsera in a research report on Wednesday. Leerink Partnrs lowered shares of Metsera from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a report on Wednesday, September 3rd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $58.50.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Want to see what other hedge funds are holding MTSR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metsera Inc. (NASDAQ:MTSR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.